Wells Fargo & Company Gilead Sciences, Inc. Transaction History
Wells Fargo & Company
- $429 Billion
- Q1 2025
A detailed history of Wells Fargo & Company transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 6,533,028 shares of GILD stock, worth $784 Million. This represents 0.17% of its overall portfolio holdings.
Number of Shares
6,533,028
Previous 6,814,812
4.13%
Holding current value
$784 Million
Previous $629 Million
16.29%
% of portfolio
0.17%
Previous 0.15%
Shares
21 transactions
Others Institutions Holding GILD
# of Institutions
2,298Shares Held
1BCall Options Held
9.42MPut Options Held
9.72M-
Black Rock Inc. New York, NY121MShares$14.5 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA119MShares$14.3 Billion0.22% of portfolio
-
State Street Corp Boston, MA59.5MShares$7.14 Billion0.28% of portfolio
-
Capital World Investors Los Angeles, CA46.3MShares$5.56 Billion0.78% of portfolio
-
Capital Research Global Investors Los Angeles, CA31.1MShares$3.73 Billion0.72% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $150B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...